AbbVie Inc.
AbbVie Reports Q3 2024 Results with Increased Revenues and Adjusted EPS
Summary
AbbVie Inc. reported its third-quarter 2024 financial results, showing a 12% decrease in GAAP diluted EPS to $0.88 and a 1.7% increase in adjusted diluted EPS to $3.00. Net revenues increased by 3.8% to $14.460 billion. The company also completed the acquisition of Cerevel, enhancing its neuroscience portfolio. Additionally, AbbVie raised its full-year 2024 adjusted diluted EPS guidance range from $10.67 - $10.87 to $10.90 - $10.94, excluding certain expenses related to IPR&D and milestones.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement